PharmatrophiX unveiled preclinical data at the Global Tau Conference further supporting evidence that LM11A-31 is a multi-action shield for the…
David Setboun, Pharm.D., MBA, CEO of PharmatrophiX, and Frank M. Longo, MD, PhD, Co-founder & Chairman, discuss LM11A-31’s upstream mechanism…
Stanford Medicine profiles LM11A-31 as a synapse-protective approach to slowing neurodegeneration.
CTAD coverage reports p-tau217 and synaptic-proteome signals over 26 weeks.
NIA summarizes safety and biomarker findings supporting larger LM11A-31 trials.
The 26-week Phase 2a trial met its primary endpoint for safety and tolerability, with biomarker and imaging signals supporting further…
JPAD review frames p75NTR as a tractable resilience pathway for neurodegeneration.
Dr. Frank Longo on hope, innovation, and a radical departure from traditional Alzheimer’s research
ADDF recognized Longo’s pioneering Alzheimer’s drug discovery work.
